Guangdong Hybribio Biotech
Launch date
Employees
Market cap
€418m
Enterprise valuation
€319m (Public information from Sep 2024)
Share price
CNY5.06 300639.SZ
Chaozhou Guangdong (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.4b | 2.7b | 5.6b | 1.1b | 1.6b | 2.1b | - |
| % growth | 86 % | 97 % | 109 % | (80 %) | 43 % | 32 % | - |
| EBITDA | 530m | 1.2b | 2.9b | 213m | - | - | - |
| % EBITDA margin | 39 % | 45 % | 52 % | 19 % | - | - | - |
| Profit | 363m | 852m | 1.7b | 140m | 144m | 175m | 216m |
| % profit margin | 27 % | 32 % | 31 % | 13 % | 9 % | 8 % | - |
| EV / revenue | 6.5x | 3.2x | 1.3x | 5.4x | 2.3x | 1.8x | - |
| EV / EBITDA | 16.7x | 7.2x | 2.5x | 28.1x | - | - | - |
| R&D budget | 71.6m | 115m | 247m | 136m | - | - | - |
| R&D % of revenue | 5 % | 4 % | 4 % | 12 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
